Shannon Puhalla, MD Assistant Professor of Medicine, Division of Hematology, University of Pittsburgh, discusses recent updates of the PALOMA-3 trial.
Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.
PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.
The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.